Cargando…

Prevalence and Risk Factors for Therapy Escalation in Ulcerative Colitis in the Swiss IBD Cohort Study

BACKGROUND: Physicians traditionally treat ulcerative colitis (UC) using a step-up approach. Given the paucity of data, we aimed to assess the cumulative probability of UC-related need for step-up therapy and to identify escalation-associated risk factors. METHODS: Patients with UC enrolled into the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Safroneeva, Ekaterina, Vavricka, Stephan R., Fournier, Nicolas, Straumann, Alex, Rogler, Gerhard, Schoepfer, Alain M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2015
Materias:	Original Clinical Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4450965/ https://www.ncbi.nlm.nih.gov/pubmed/25806845 http://dx.doi.org/10.1097/MIB.0000000000000368

Ejemplares similares

Impact of Diagnostic Delay on Disease Course in Pediatric- versus Adult-Onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort
por: Schoepfer, Alain M., et al.
Publicado: (2021)

Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study
por: Bon, Lorenz, et al.
Publicado: (2019)

The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients
por: Roth, René, et al.
Publicado: (2021)

Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014
por: Bähler, Caroline, et al.
Publicado: (2017)

Impact of Overweight and Obesity on Disease Outcome in the Pediatric Swiss Inflammatory Bowel Disease Cohort
por: von Graffenried, Thea, et al.
Publicado: (2022)

The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort
por: Hiller, Aimee, et al.
Publicado: (2019)

Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study
por: Schüle, Solvey, et al.
Publicado: (2017)

Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
por: Roth, Nina, et al.
Publicado: (2019)

Risk factors for complications in patients with ulcerative colitis
por: Manser, Christine N, et al.
Publicado: (2016)

Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study
por: Biedermann, Luc, et al.
Publicado: (2019)

Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account
por: Zeitz, Jonas, et al.
Publicado: (2016)

Extraintestinal Manifestations of Inflammatory Bowel Disease
por: Vavricka, Stephan R., et al.
Publicado: (2015)

Close follow‐up is associated with fewer stricture formation and results in earlier detection of histological relapse in the long‐term management of eosinophilic esophagitis
por: Bon, Lorenz, et al.
Publicado: (2022)

Lifestyle factors associated with inflammatory bowel disease: data from the Swiss IBD cohort study
por: Lautenschlager, Severin A., et al.
Publicado: (2023)

Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort
por: Spalinger, Marianne R., et al.
Publicado: (2016)

Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study
por: Grob, Lorenz, et al.
Publicado: (2020)

The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients
por: Yilmaz, Bahtiyar, et al.
Publicado: (2018)

Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn’s disease patients
por: Greuter, Thomas, et al.
Publicado: (2018)

Anemia in Inflammatory Bowel Disease: An Under-Estimated Problem?
por: Rogler, Gerhard, et al.
Publicado: (2015)

Assessing the Clinical and Endoscopic Efficacy of Extended Treatment Duration with Different Doses of Mesalazine for Mild-to-Moderate Ulcerative Colitis beyond 8 Weeks of Induction
por: D’Haens, Geert, et al.
Publicado: (2023)

Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland
por: Perrig, Kathrin, et al.
Publicado: (2022)

Effect of closed and permanent stoma on disease course, psychological well-being and working capacity in Swiss IBD cohort study patients
por: Bianchi, Rahel, et al.
Publicado: (2022)

Therapy Patterns and Surveillance Measures of Inflammatory Bowel Disease Patients beyond Disease-Related Hospitalization: A Claims-Based Cohort Study
por: Bähler, Caroline, et al.
Publicado: (2022)

Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study
por: Pugliese, Daniela, et al.
Publicado: (2021)

Predictors of Response to Vedolizumab in Patients with Ulcerative Colitis: Results from the Greek VEDO-IBD Cohort
por: Bamias, Giorgos, et al.
Publicado: (2021)

Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)
por: Jentzer, Alexandre, et al.
Publicado: (2020)

A146 THE EFFECTIVENESS OF USTEKINUMAB DOSE ESCALATION IN PATIENTS WITH ULCERATIVE COLITIS
por: Albino, L, et al.
Publicado: (2022)

Presence of pseudopolyps in ulcerative colitis is associated with a higher risk for treatment escalation
por: Politis, Dimitrios S., et al.
Publicado: (2019)

Efficacy and safety of tofacitinib dose de‐escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open
por: Sands, Bruce E., et al.
Publicado: (2019)

Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease
por: Martinho-Grueber, Maude, et al.
Publicado: (2022)

Genetic risk factors predict disease progression in Crohn’s disease patients of the Swiss inflammatory bowel disease cohort
por: Ditrich, Felicitas, et al.
Publicado: (2020)

Medication Formulation Preference of Mild and Moderate Ulcerative Colitis Patients: a European Survey
por: Hébuterne, Xavier, et al.
Publicado: (2023)

Retrospective Database Analysis: Dose Escalation and Adherence in Patients Initiating Biologics for Ulcerative Colitis
por: Long, Millie D., et al.
Publicado: (2022)

Dose escalation randomised study of efmarodocokin alfa in healthy volunteers and patients with ulcerative colitis
por: Wagner, Frank, et al.
Publicado: (2023)

Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis
por: Roth, Sofia, et al.
Publicado: (2016)

Peripheral Blood Based Discrimination of Ulcerative Colitis and Crohn’s Disease from Non-IBD Colitis by Genome-Wide Gene Expression Profiling
por: Sipos, Ferenc, et al.
Publicado: (2011)

Systematic Literature Review of Real-World Evidence on Dose Escalation and Treatment Switching in Ulcerative Colitis
por: Singh, Harpreet, et al.
Publicado: (2023)

Validation of the ‘Inflammatory Bowel Disease—Distribution, Chronicity, Activity [IBD-DCA] Score’ for Ulcerative Colitis and Crohn´s Disease
por: Lang-Schwarz, Corinna, et al.
Publicado: (2021)

Real-World Effectiveness and Safety of Ustekinumab for Ulcerative Colitis From 2 Tertiary IBD Centers in the United States
por: Hong, Simon J, et al.
Publicado: (2021)

High prevalence of ulcerative appendicitis in patients with ulcerative colitis
por: Heuthorst, Lianne, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9sckv4lpg8argv4ioh9b4gqt6h